IsZo Capital Holds Approximately 5.2% Of Liquidia In A Passive Position
The fund's 4,712,900 shares carry shared voting and disposal authority for its related reporting persons.
IsZo Capital LP reported an approximately 5.2% stake in Liquidia, which develops and sells treatments for respiratory and vascular diseases. Its SEC ownership disclosure filed Thursday classified the fund's position as passive and put the holding at 4,712,900 common shares at Thursday's close of business.
One Holding, Shared Authority
IsZo Capital LP holds the shares. Its general partner, IsZo Capital GP, its investment manager, IsZo Capital Management, and Brian L. Sheehy each reported the same position as shares they may be deemed to beneficially own.
Sheehy is managing member of the fund's general partner and president of the investment manager's general partner. The related reporting persons share the power to vote the holding and decide whether to sell it; the ownership figures refer to the fund's shares.
The approximately 5.2% figure uses 90,106,442 outstanding shares as its base. Liquidia reported that count as of October 28, 2026, in its quarterly report filed Tuesday.
The reporting persons certified that they neither bought nor hold the securities to change or influence Liquidia's control, or to participate in a transaction aimed at doing so.
YUTREPIA Anchors Liquidia's Business
Liquidia's main treatment markets are pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its revenue sources include YUTREPIA, a dry-powder version of treprostinil that patients inhale through a dry-powder inhaler.
YUTREPIA received U.S. Food and Drug Administration approval in May 2025 and launched in June 2025. Liquidia's U.S. field sales team calls on healthcare providers treating patients with these diseases.
The company also shares profits from Sandoz's generic treprostinil injection in the United States through a promotion agreement. Alongside its commercial business, Liquidia researches, develops and manufactures new products, including L606, a liposomal treprostinil candidate in clinical studies.
Liquidia's recent financial trajectory has combined revenue growth with wider losses, the subject of coverage published Wednesday.
Sources
- SCHEDULE 13G — IsZo Capital LP re: Liquidia Corp ("Issuer") (LQDA) — SEC EDGAR
- SCHEDULE 13G Exhibit 99 — IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP — SEC EDGAR
- Liquidia Corp. (NASDAQ:LQDA) : Articles :: Law360 — law360.com
- Will Revenue Growth And Wider Losses Change Liquidia (LQDA) Stock Narrative — Yahoo Finance